News

Eli Lilly and Company and AstraZeneca, who previously partnered to study an investigational treatment for Alzheimer’s disease, have announced the enrollment of the first patient in the study, called AMARANTH. The Phase II/III study aims to evaluate the safety and efficacy of oral beta secretase cleaving…

High levels of testosterone may be connected with higher risk for hallucinations, aggression and other acting-out actions in men that already have Alzheimer’s disease. Lower testosterone levels increase the risk of developing Alzheimer’s disease, according to studies. However, once the onset of Alzheimer’s is established, higher levels of…

A recent study published in the journal eLife suggests that it might be possible to restore lost memories. Over the past century, evidence suggested that long-term memories are expressed in the brain by changes in synaptic connections, which are destroyed in neurodegenerative disorders. However, in a recent news…

A 30 million euro call for research in neurodegenerative disease was recently announced by the EU Joint Programme – Neurodegenerative Disease Research (JPND). The program will receive an additional 10 million in funding from the Horizon 2020 framework program for research and innovation of the European Union. Alzheimer’s, Parkinson’s and other…

The U.S. Food and Drug Administration (FDA) has granted Arjuna Natural Extracts Ltd. a U.S. patent for the company’s turmeric extract formulation, BCM-95 Curcumin, which is expected to become a treatment for patients suffering from Alzheimer’s disease. The patent number 8859020 describes the drugs’s combination of beneficial curcuminoids and turmeric…

The Neurodegeneration Medicines Acceleration Program (Neuro-MAP) led by MRC Technology is a non-profit organization that brings together promising drug projects for brain diseases like Parkinson’s and Alzheimer’s that have stalled due to lack of support with funding organizations. Their goal is to revive these projects by helping scientists continue their…

A Stanford University School of Medicine study recently published in the Journal of Clinical Investigation, entitled “Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models,” indicate that microglia impairment may be under the cause of Alzheimer’s disease. The cause of Alzheimer’s disease (AD) is…

Biotech industry veteran Tony Coles, M.D. has launched a new startup — Cambridge, Massachusetts-based Yumanity Therapeutics. Founded in December 2014, the new company’s central focus is on drug discovery for diseases caused by a DNA anomaly called “protein misfolding.” Yumanity Therapeutics’ founders include by Dr. Coles, who is…

A new study on Dementia with Lewy bodies (DLB) and Corticobasal Syndrome (CBS) entitled “Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography” was published in Alzheimer’s Research & Therapy by Michael R Misch, part…

A new study is now enrolling and accepting volunteers to investigate the potential of a new drug to slow the devastating effects of Alzheimer’s disease on patients’ memory and physical activity. Eligible participants include men and women with ages between 55 to 85 years old suffering from mild to severe Alzheimer’s.